Next-generation sequencing (NGS) has revolutionized the diagnostic and research landscape for solid tumors by enabling comprehensive detection of somatic mutations, structural variants, gene fusions, and expression profiles. These advancements have provided key molecular insights that inform clinical decision-making and therapeutic stratification. Emerging “Second-Next-Generation” sequencing technologies are set to overcome the limitations of earlier approaches, such as narrow targeted panels and bulk sequencing, which often obscure tumor heterogeneity. Together, these developments promise unprecedented resolution in the molecular characterization and classification of solid tumors. In parallel, rapid advances in artificial intelligence (AI) and large language models (LLMs) are poised to transform data processing, interpretation, and clinical integration of NGS results. This review discusses the most promising technological innovations driving this next era of sequencing and their transformative implications for solid tumor diagnostics and translational oncology.